

Pace Biotech

Surajpur, Paonta sahib Dist. Sirmour (H.P)

Title	: Certificate of Analysis Finished Product				
D. L. A Name	Imstatin-500 Injection	A.R. No.	BD/FP/23/814		
Product Name	Imipenem & Cilastatin Injection IP 500mg	Sampled qty.	45 Vials		
Generic Name	B23726A	Sampled by	Arvind		
Batch No.	1000 Vials	Sampled on	17/03/2024		
Batch Size	02/2024	Date of Testing	17/03/2024		
Mfg. Date		Date of conditionally	26/03/2024		
Exp. Date	01/2026	Release	20/03/2021		

S. No.	Tests	Specifications			Observa	
	Description	A white dry powder filled in clear glass vial.			A white dry powder fille in clear glass vial.	
2.	Identification	In the Assay, the principal peaks in the chromatogram obtained with the test solution corresponds to the peak in the Chromatogram obtained with the working standard solution.		ne test in the		Complies
3.	Uniformity of Weight	Average weight ±10%		-0.64% & +0.64%		
4 .	Average weight	Informative.		1108.8 mg		
5.	pH	6.5 to 8.5		7.29		
6.	Loss on drying	NMT- 3.5% w/w		1.94%w/w		
7.	Particulate Matter					
	 (a.) Sub-Visible particle count (1.) Particles ≥10μm (2.) Particles ≥25μm (b.) Visual 	NMT-6000/vial NMT-600/ vial The solution is free from particles of foreign matter particles that can be observed on visual inspection.				
8.	Sterility	No microbial growth should be observed.				
9.	Bacterial Endotoxins	NMT- 0.17 EU/n Cilastatin.	ng of Imipener	n &	Less than- 0.17 EU/mg of Imipenem & Cilastatin.	
10.	Assay: Each glass vial Contains		D 1	% of la	ahalad	Limits % of
Ingredients		Labeled Claim	Found	amo		labeled amount
Sterile Imipenem I.P Eq. to Anhydrous Imipenem		500 mg	520.65 mg	104.	.13% 90.0 to 115%	
Sterile Cilastatin Sodium I.P Eq. to Cilastatin (Sodium Bicarbonate IP added as buffer) Remarks: In the opinion of the understanding the standard s		500 mg	518.42 mg		68%	90.0 to 115%

Drug & Cosmetic Act 1940 and the rules made there under. Complies not complies as per IP/BP/USP/IHS.

Analysis by

Checked by

Approved by